Whole Blood Transfusion for Severe Malarial Anemia in a High Plasmodium falciparum Transmission Setting.
Matthew M Ippolito, Jean-Bertin B Kabuya, Manuela Hauser...
https://pubmed.ncbi.nlm.nih.gov/35439307/Actively Recruiting
Led by Johns Hopkins Bloomberg School of Public Health · Updated on 2026-09-11
132
Participants Needed
2
Research Sites
56 weeks
Total Duration
Researchers are evaluating the use of whole blood transfusion to improve survival in children aged 1 month to 5 years who have severe malaria complicated by low platelet counts thrombocytopenia. This randomized controlled trial aims to compare outcomes between children who receive a transfusion and those who do not, focusing on survival until hospital discharge or death. The trial is part of a larger study on severe malaria and is conducted in multiple centers. Participants will be randomly assigned to receive either a single whole blood transfusion at a dose of 20 mL per kilogram of body weight or standard care without transfusion. The whole blood is provided by the Zambia National Blood Transfusion Service. Children will be monitored closely during their hospital stay, with treatment given according to their assigned group. Throughout the study, researchers will collect blood samples before and after transfusion to measure changes in hemoglobin, platelet count, and white blood cell count. They will also track the occurrence of transfusion reactions, length of hospital stay, and parasite clearance every 12 hours for up to 72 hours. The primary outcome is all-cause mortality up to hospital discharge or death, typically within 28 days. Participants will be followed until discharge or death, with detailed monitoring during hospitalization.
CONDITIONS
Platelet-Directed Whole Blood Transfusion Strategy for Malaria
M
Matthew M Ippolito, MD PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Johns Hopkins Bloomberg School of Public Health
Lead Sponsor
Johns Hopkins University
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Whole blood transfusion (trial arm) | No transfusion (trial control) | WHO‑recommended transfusion threshold |
|---|---|---|---|
| What it is | An investigational strategy where children with severe malaria and thrombocytopenia receive whole blood transfusion. | A control arm where no transfusion is given to children meeting severe malaria and thrombocytopenia criteria. | Current WHO guidance recommends blood transfusion only when hemoglobin falls below defined severe anemia thresholds, not based on platelet count alone. |
| Role in the trial | Assigned randomized intervention being evaluated for supportive care in malaria. | Assigned randomized comparator representing usual absence of transfusion in this setting. | Represents the standard decision point used in most settings—transfusion based on severe anemia hemoglobin thresholds. |
| Primary use | Supportive whole blood transfusion to correct severe malaria‑associated thrombocytopenia and anemia. | Usual supportive care without transfusion. | Supportive blood transfusion when hemoglobin indicates severe anemia as per WHO thresholds. |
| How it is given or performed | Whole blood donated via national blood service is transfused to eligible children. | No transfusion procedure is performed. | Transfusion performed when hemoglobin is below severe anemia threshold, typically after testing hemoglobin levels as per WHO protocols. |
| Evidence status | Effectiveness not yet established; trial is ongoing. | No evidence of benefit; comparator condition in trial context. | Evidence supports transfusion when indicated by severe anemia thresholds in reducing mortality in severe malaria per WHO guidance. |
| Important risks | Risks include transfusion‑related reactions which are monitored up to hospital discharge or in‑hospital death. | No transfusion eliminates transfusion‑related risks. | Transfusions carry known risks such as reactions or infections; standard practice includes safety monitoring. |
| Important limitations | Trial results may not generalize to settings with limited blood supply or different anemia thresholds. | Not applicable outside the controlled trial context where withholding transfusion may not reflect standard care. | Hemoglobin‑based thresholds may delay transfusion in patients with severe thrombocytopenia who are at risk before anemia develops. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to hospital discharge or in-hospital death, up to 28 days
Participants receive either a single whole blood transfusion or standard care without transfusion, according to random assignment.
Daily monitoring during hospitalization
Duration - Up to hospital discharge or in-hospital death, up to 28 days
Researchers monitor participants for changes in blood counts, parasite clearance, transfusion reactions, and length of hospital stay until discharge or death.
Regular assessments during hospitalization
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Matthew M Ippolito, Jean-Bertin B Kabuya, Manuela Hauser...
https://pubmed.ncbi.nlm.nih.gov/35439307/Johns Hopkins Bloomberg School of Public Health
Lead Sponsor
Johns Hopkins University
Collaborating Sponsor